Our sensitivity analysis additionally bolsters support for quantification of any AD-related biomarker, even amyloidosis alone, as the inclusion of AD-tau data in our categorization of baseline AD presence did not alter the observed pattern of results. This evidence concerns the gene MAPT and amyloidosis.